Overview

Relative Bioavailability and Food Effect Study

Status:
Completed
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
Primary objective: To determine oral bioavailability of the liquid formulation intended for pediatric use and potential food effects in healthy adults. Secondary objective: To evaluate safety and tolerability measured by physical examination findings, vital signs, electrocardiogram (ECG), laboratory parameters, and adverse events (AEs).
Phase:
Phase 1
Details
Lead Sponsor:
Bayer
Treatments:
Riociguat